Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively (NCT05568719)

🧪 Interventions in This Study

• Testing of hepatic AAV Vector integration (DIAGNOSTIC_TEST)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (23 Sites)

• The Regents of the University of California||UC Davis Health — Rancho Cordova, California
• UC Davis Health — Sacramento, California
• UC Davis Ambulatory Care Clinic — Sacramento, California
• UC Davis Hemophilia Treatment Center — Sacramento, California
• UC Davis Medical Center — Sacramento, California
• UCSF Outpatient Hematology Clinic — San Francisco, California
• USF Health Morsani Center For Advanced Healthcare — Tampa, Florida
• The University of South Florida Board of Trustees — Tampa, Florida
• Mississippi Center For Advanced Medicine — Madison, Mississippi
• Cornell University||Joan & Sanford I. Weill Medical College — New York, New York
• Weill Cornell Medical College-New York Presbyterian Hospital — New York, New York
• The Childrens Hospital of Philadelphia Division of Hematology — Philadelphia, Pennsylvania
• The Childrens Hospital of Philadelphia Division of Hematology — Philadelphia, Pennsylvania
• Washington Institute for Coagulation — Seattle, Washington
• Royal Prince Alfred Hospital — Camperdown, New South Wales
• Sydney Local Health District (RPAH Zone) — Camperdown, New South Wales
• Unity Health Toronto, St. Michael's Hospital — Toronto, Ontario
• Kyung Hee University Hospital at Gangdong — Seoul,
• Skåne University Hospital — Malmö,
• Taichung Veterans General Hospital — Taichung,
• National Taiwan University Hospital — Taipei,
• Ege Universitesi Hastanesi — Izmir, İ̇zmir
• Acibadem Adana Hospital — Adana,

📞 Contact the Study Coordinator

Phone: (800) 718-1021

Email: ClinicalTrials.gov_Inquiries@pfizer.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hemophilia A

• Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle" — Little Rock, Arkansas
• Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A — Los Angeles, California
• Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A — Milwaukee, Wisconsin
• A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A — Gainesville, Florida
• A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A — Gilbert, Arizona
• Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults — Mountain View, California

Explore by condition: All Hemophilia A clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.